Search Results for: Cybin

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA, Laughren oversaw the review of all psychiatric drug-development activities conducted under Investigational New Drug … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board”

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale will provide an overview of the company, including key information targeting the forum audience. Drysdale’s presentation is scheduled for 9 … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Participation at Life Sciences Investor Forum”

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational New Drug (“IND”) process. The 51st study was an in-vitro and in-vivo evaluation of Cybin’s growing number of psychedelic compounds being … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes 51st Pre-Clinical Psychedelic Molecule Study”

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced that its CEO Doug Drysdale will be participating at the 2021 Emerging Growth Conference, which is scheduled for June 23, 2021.As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at the Emerging Growth Conference”

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be part of the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond conference. The all-virtual conference is slated for June 17, 2021. During the conference, Cybin CEO Doug Drysdale will be presenting on Cybin and its business and strategy, as well … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Participate at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference”

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin announced that the randomized, placebo-controlled trial will evaluate psychedelic-assisted psychotherapy with psilocybin in the treatment of  symptoms of depression, anxiety, … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Develops New Treatment Model, Announces Co-Sponsorship of First-Ever Trial to Treat Frontline Clinicians”

Cybin (NEO: CYBN) (OTCQB: CLXPF) CEO Doug Drysdale will be participating at the 2021 LD Micro Invitational XI. The invitational will be held Thursday, June 10. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at Upcoming LD Micro Invitational XI”